|
1
|
Garrett TPJ, McKern NM, Lou M, Elleman TC,
Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, et
al: Crystal structure of a truncated epidermal growth factor
receptor extracellular domain bound to transforming growth factor
alpha. Cell. 110:763–773. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ogiso H, Ishitani R, Nureki O, Fukai S,
Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M and
Yokoyama S: Crystal structure of the complex of human epidermal
growth factor and receptor extracellular domains. Cell.
110:775–787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ciardiello F and Tortora G: EGFR
antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgillo F, Della Corte CM, Fasano M and
Ciardiello F: Mechanisms of resistance to EGFR-targeted drugs: Lung
cancer. ESMO Open. 1:e0000602016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Misale S, Yaeger R, Hobor S, Scala E,
Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M,
Siravegna G, et al: Emergence of KRAS mutations and acquired
resistance to anti-EGFR therapy in colorectal cancer. Nature.
486:532–536. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Alewine C, Hassan R and Pastan I: Advances
in anticancer immunotoxin therapy. Oncologist. 20:176–185. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kreitman RJ, Tallman MS, Robak T, Coutre
S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R and
Pastan I: Phase I trial of anti-CD22 recombinant immunotoxin
moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy
cell leukemia. J Clin Oncol. 30:1822–1828. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hassan R, Bullock S, Premkumar A, Kreitman
RJ, Kindler H, Willingham MC and Pastan I: Phase I study of SS1P, a
recombinant anti-mesothelin immunotoxin given as a bolus I.V.
infusion to patients with mesothelin-expressing mesothelioma,
ovarian, and pancreatic cancers. Clin Cancer Res. 13:5144–5149.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kreitman RJ, Hassan R, Fitzgerald DJ and
Pastan I: Phase I trial of continuous infusion anti-mesothelin
recombinant immunotoxin SS1P. Clin Cancer Res. 15:5274–5279. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mason-Osann E, Hollevoet K, Niederfellner
G and Pastan I: Quantification of recombinant immunotoxin delivery
to solid tumors allows for direct comparison of in vivo and in
vitro results. Sci Rep. 5:108322015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mazor R, Crown D, Addissie S, Jang Y,
Kaplan G and Pastan I: Elimination of murine and human T-cell
epitopes in recombinant immunotoxin eliminates neutralizing and
anti-drug antibodies in vivo. Cell Mol Immunol. 14:432–442. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dennis MS, Zhang M, Meng YG, Kadkhodayan
M, Kirchhofer D, Combs D and Damico LA: Albumin binding as a
general strategy for improving the pharmacokinetics of proteins. J
Biol Chem. 277:35035–35043. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siontorou CG: Nanobodies as novel agents
for disease diagnosis and therapy. Int J Nanomedicine. 8:4215–4227.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hou X, Meehan EJ, Xie J, Huang M, Chen M
and Chen L: Atomic resolution structure of cucurmosin, a novel type
1 ribosome-inactivating protein from the sarcocarp of Cucurbita
moschata. J Struct Biol. 164:81–87. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang B, Huang H, Xie J, Xu C, Chen M,
Wang C, Yang A and Yin Q: Cucurmosin induces apoptosis of BxPC-3
human pancreatic cancer cells via inactivation of the EGFR
signaling pathway. Oncol Rep. 27:891–897. 2012.PubMed/NCBI
|
|
18
|
Xie J, Que W, Liu H, Liu M, Yang A and
Chen M: Anti-proliferative effects of cucurmosin on human hepatoma
HepG2 cells. Mol Med Rep. 5:196–201. 2012.PubMed/NCBI
|
|
19
|
Xie J, Wang C, Zhang B, Yang A, Yin Q,
Huang H and Chen M: Cucurmosin induces the apoptosis of human
pancreatic cancer CFPAC-1 cells by inactivating the PDGFR-β
signalling pathway. Pharmacol Rep. 65:682–688. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie J, Wang C, Yang A, Zhang B, Yin Q,
Huang H and Chen M: Cucurmosin kills human pancreatic cancer
SW-1990 cells in vitro and in vivo. Anticancer Agents Med Chem.
13:952–956. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deng C, Xiong J, Gu X, Chen X, Wu S, Wang
Z, Wang D, Tu J and Xie J: Novel recombinant immunotoxin of EGFR
specific nanobody fused with cucurmosin, construction and antitumor
efficiency in vitro. Oncotarget. 8:38568–38580. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roovers RC, Vosjan MJ, Laeremans T, el
Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA
and van Bergen en Henegouwen PM: A biparatopic anti-EGFR nanobody
efficiently inhibits solid tumour growth. Int J Cancer.
129:2013–2024. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Greenhalgh J, Dwan K, Boland A, Bates V,
Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of
advanced epidermal growth factor receptor (EGFR) mutation positive
non-squamous non-small cell lung cancer. Cochrane Database Syst
Rev. CD0103832016.PubMed/NCBI
|
|
24
|
Jean GW and Shah SR: Epidermal growth
factor receptor monoclonal antibodies for the treatment of
metastatic colorectal cancer. Pharmacotherapy. 28:742–754. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee JJ and Chu E: First-line use of
anti-epidermal growth factor receptor monoclonal antibodies in
metastatic colorectal cancer. Clin Colorectal Cancer. 2 (Suppl
6):S42–S46. 2007. View Article : Google Scholar
|
|
26
|
Simon N and FitzGerald D: Immunotoxin
therapies for the treatment of epidermal growth factor
receptor-dependent cancers. Toxins (Basel). 8:1372016. View Article : Google Scholar
|
|
27
|
Cheung LS, Fu J, Kumar P, Kumar A,
Urbanowski ME, Ihms EA, Parveen S, Bullen CK, Patrick GJ, Harrison
R, et al: Second-generation IL-2 receptor-targeted diphtheria
fusion toxin exhibits antitumor activity and synergy with anti-PD-1
in melanoma. Proc Nat Acad Sci U S A. 116:3100–3105. 2019.
View Article : Google Scholar
|
|
28
|
Xiong J, Zhang C, Wu S, Gu X, Cai Y, Xu C,
Chen Z, Sun J, Wu X, You X, et al: Recombinant cucurmosin-based
immunotoxin targeting HER-2 with potent in vitro anti-cancer
cytotoxicity. Biochem Biophys Res Commun. 513:15–21. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang C, Xiong J, Lan Y, Wu J, Wang C,
Huang Z, Lin J and Xie J: Novel cucurmosin-based immunotoxin
targeting programmed cell death 1-ligand 1 with high potency
against human tumor in vitro and in vivo. Cancer Sci.
111:3184–3194. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schmohl JU, Todhunter D, Taras E,
Bachanova V and Vallera DA: Development of a deimmunized bispecific
immunotoxin dDT2219 against B-cell malignancies. Toxins (Basel).
10:322018. View Article : Google Scholar
|
|
31
|
Sanz L, Blanco B and Alvarez-Vallina L:
Antibodies and gene therapy: Teaching old ‘magic bullets’ new
tricks. Trends Immunol. 25:85–91. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Roovers RC, Laeremans T, Huang L, De Taeye
S, Verkleij AJ, Revets H, de Haard HJ and van Bergen en Henegouwen
PMP: Efficient inhibition of EGFR signaling and of tumour growth by
antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother.
56:303–317. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tijink BM, Laeremans T, Budde M,
Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR and van
Dongen GAMS: Improved tumor targeting of anti-epidermal growth
factor receptor Nanobodies through albumin binding: Taking
advantage of modular nanobody technology. Mol Cancer Ther.
7:2288–2297. 2008. View Article : Google Scholar : PubMed/NCBI
|
